Headlines about Evoke Pharma (NASDAQ:EVOK) have been trending somewhat positive on Thursday, according to Accern Sentiment Analysis. Accern identifies positive and negative media coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Evoke Pharma earned a news impact score of 0.21 on Accern’s scale. Accern also assigned media coverage about the specialty pharmaceutical company an impact score of 45.7304680696725 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

Several analysts have weighed in on EVOK shares. ValuEngine upgraded shares of Evoke Pharma from a “sell” rating to a “hold” rating in a research note on Thursday, July 20th. HC Wainwright reiterated a “buy” rating and set a $9.00 target price on shares of Evoke Pharma in a research note on Monday, September 18th. Zacks Investment Research upgraded shares of Evoke Pharma from a “strong sell” rating to a “hold” rating in a research note on Thursday, October 12th. Seaport Global Securities reiterated a “buy” rating and set a $10.00 target price on shares of Evoke Pharma in a research note on Friday, October 6th. Finally, FBR & Co reiterated a “buy” rating and set a $10.00 target price on shares of Evoke Pharma in a research note on Thursday. One analyst has rated the stock with a sell rating, two have given a hold rating and six have given a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $8.86.

Evoke Pharma (NASDAQ:EVOK) traded down 0.88% during midday trading on Thursday, reaching $3.37. 205,931 shares of the company traded hands. Evoke Pharma has a 12-month low of $1.35 and a 12-month high of $4.55. The company’s market cap is $51.86 million. The company has a 50-day moving average price of $3.33 and a 200-day moving average price of $2.76.

Evoke Pharma (NASDAQ:EVOK) last announced its earnings results on Monday, August 14th. The specialty pharmaceutical company reported ($0.27) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.12) by ($0.15). During the same quarter in the prior year, the business posted ($0.41) earnings per share. On average, analysts predict that Evoke Pharma will post ($0.87) earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This news story was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this news story on another domain, it was copied illegally and republished in violation of US & international copyright and trademark legislation. The legal version of this news story can be accessed at https://www.thecerbatgem.com/2017/10/19/somewhat-positive-press-coverage-somewhat-unlikely-to-affect-evoke-pharma-evok-share-price.html.

About Evoke Pharma

Evoke Pharma, Inc is a specialty pharmaceutical company. The Company is focused primarily on the development of drugs to treat gastrointestinal (GI) disorders and diseases. The Company is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women.

Insider Buying and Selling by Quarter for Evoke Pharma (NASDAQ:EVOK)

Receive News & Stock Ratings for Evoke Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma Inc. and related stocks with our FREE daily email newsletter.